Vaccine Development Partners
Barry Garfinkle & Associates Consulting LLC
Dr. Garfinkle has over 30 years of experience in the development and manufacture of human vaccines, biologicals and sterile pharmaceuticals at Merck. Dr. Garfinkle is an invaluable resource to Syntiron in the development of viable human vaccine candidates.
Mr. Douglas Freitag is the President of Bayside Materials Technology, a company established in 1993 to help companies with federal business development, government affairs and technology transition. Mr. Freitag serves as Syntiron’s Washington advocate and has been an integral part in developing relationships with NIH, DTRA, NMRC and other important US government agencies.
Dr. Norman Baylor, who worked 20 years with the Food and Drug Administration (FDA), most recently as the Director of the Office of Vaccines Research and Review (OVRR) and as the FDA’s liaison to CDC’s Advisory Committee on Immunization Practices and the DHHS National Vaccine Advisory Committee has advised Syntiron on the regulatory approval process for our pipeline vaccine candidates. Dr. Tom Gerteisen, with over 30 years of experience in quality systems in the biopharmaceutical industry (Bayer Corporation, Biogen Idec, Genzyme), has provided assistance to Syntiron in the assessment and expansion of our quality systems in anticipation of filing our first IND.
In 2009, Syntiron received a $4.1 million contract from the US Defense Threat Reduction Agency (DTRA) for the development of vaccines to protect against three potential bacterial biowarfare agents – Bacillus anthracis (anthrax), Yersinia pestis (plague) and Burkholderia pseudomallei (melioidosis).
Syntiron holds an exclusive license to the Epitopix SRP® technology patent portfolio for all human vaccine applications. Epitopix has proven SRP® Technology to be safe and effective in millions of animals of various species.
Syntiron retains Fredrikson & Byron as primary legal counsel. Mr. Ryan Miest serves as Corporate Attorney to Syntiron. Mr. Miest’s practice focuses on representation of technology-driven enterprises ranging from start-ups to publicly-traded corporations in the areas of mergers and acquisitions, corporate finance and securities, strategic intellectual property monetization and technology transactions.
Syntiron is proud to be a member of LifeScience Alley, a Minnesota-based trade organization with nearly 700 member organizations. LifeScience Alley affords Syntiron significant benefits such as educational seminars, invaluable networking opportunities, and advocacy in legislative and regulatory matters at local, state and federal levels.
Mueting, Raasch & Gebhardt act as Syntiron’s advisors in all issues related to intellectual property law, including patent preparation, prosecution and opinions.
Since 2006, Syntiron has been awarded six Small Business Innovation Research grants from the National Institute for Allergy and Infectious Disease (NIAID) for the research and development of vaccines against E. coli, Salmonella spp., Staphylococcus aureus and Yersinia pestis.
Sanofi Pasteur worked with Syntiron on a three-year collaborative research development project to develop a vaccine against Staphylococcus aureus. S. aureus, including MRSA, continues to be one of Syntiron’s most important pipeline targets.
Syntiron’s close ties with the University of Minnesota have resulted in several scientific collaborations with professors, numerous synergistic business relationships with other companies and faculty, and career development opportunities for University students in the Syntiron laboratory. Syntiron scientists also periodically teach and present research to University students.
Syntiron worked with the US Medical Countermeasures and Vaccines Biological Defense Research Directorate at the Naval Medical Research Center (NMRC) as a partner under its DTRA contract. Syntiron is currently investigating additional biodefense opportunities.